TY  - JOUR
A1  - Hecht, Markus
A1  - Hahn, Dennis
A1  - Wolber, Philipp
A1  - Hautmann, Matthias Günther
A1  - Reichert, Dietmar
A1  - Weniger, Steffi
A1  - Belka, Claus
A1  - Bergmann, Tobias
A1  - Göhler, Thomas
A1  - Welslau, Manfred
A1  - Große-Thie, Christina
A1  - Guntinas-Lichius, Orlando
A1  - Müller-von der Grün, Jens
A1  - Balermpas, Panagiotis
A1  - Orlowski, Katrin
A1  - Messinger, Diethelm
A1  - Stenzel, Karsten G.
A1  - Fietkau, Rainer
T1  - A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer
T2  - Cancers
N2  - Treatment options of locoregional recurrent head and neck squamous cell cancer (HNSCC) include both local strategies as surgery or re-radiotherapy and systemic therapy. In this prospective, multi-center, non-interventional study, patients were treated either with platinum-based chemotherapy and cetuximab (CT + Cet) or re-radiotherapy and cetuximab (RT + Cet). In the current analysis, progression-free survival (PFS) and overall survival (OS) were compared in patients with locoregional recurrence. Four hundred seventy patients were registered in 97 German centers. After exclusion of patients with distant metastases, a cohort of 192 patients was analyzed (129 CT + Cet, 63 RT + Cet). Radiotherapy was delivered as re-irradiation to 70% of the patients. The mean radiation dose was 51.8 Gy, whereas a radiation dose of ≥60 Gy was delivered in 33% of the patients. Chemotherapy mainly consisted of cisplatin/5-flurouracil (40%) or carboplatin/5-flurouracil (29%). The median PFS was 9.2 months in the RT + Cet group versus 5.1 months in the CT + Cet group (hazard ratio for disease progression or death, 0.40, 95% CI, 0.27–0.57, p < 0.0001). Median OS was 12.8 months in the RT + Cet group versus 7.9 months in the CT + Cet group (hazard ratio for death, 0.50, 95% CI, 0.33–0.75, p = 0.0008). In conclusion, radiotherapy combined with cetuximab improved survival compared to chemotherapy combined with cetuximab in locally recurrent HNSCC.
KW  - HNSCC
KW  - cetuximab
KW  - re-irradiation
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63218
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-632182
SN  - 2072-6694
N1  - This research was funded by Merck Serono GmbH, an affiliate of Merck KGaA, Darmstadt, Germany.
VL  - 13
IS  - 14, art. 3413
SP  - 1
EP  - 11
PB  - MDPI
CY  - Basel
ER  -